Vera Therapeutics, Inc. $VERA Holdings Decreased by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 24.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,051,583 shares of the company’s stock after selling 340,838 shares during the period. Pictet Asset Management Holding SA owned approximately 1.47% of Vera Therapeutics worth $42,305,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. GAMMA Investing LLC grew its stake in Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after acquiring an additional 236 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Vera Therapeutics in the fourth quarter worth approximately $46,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Vera Therapeutics during the fourth quarter worth approximately $71,000. Quantbot Technologies LP acquired a new stake in shares of Vera Therapeutics during the second quarter worth approximately $51,000. Finally, Sandia Investment Management LP purchased a new position in Vera Therapeutics during the fourth quarter valued at approximately $127,000. 99.21% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $37.93, for a total value of $701,705.00. Following the completion of the sale, the chief executive officer owned 198,244 shares of the company’s stock, valued at approximately $7,519,394.92. The trade was a 8.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 59,951 shares of company stock valued at $2,392,387. 15.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on VERA shares. Wolfe Research upgraded shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research note on Wednesday, March 11th. The Goldman Sachs Group reissued a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Jefferies Financial Group restated a “buy” rating and set a $60.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Finally, Evercore set a $91.00 price objective on Vera Therapeutics in a research report on Friday, May 15th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $78.00.

Vera Therapeutics Price Performance

Shares of VERA opened at $42.91 on Wednesday. The firm has a market cap of $3.08 billion, a PE ratio of -7.75 and a beta of 0.93. The firm’s 50 day moving average price is $36.09 and its 200 day moving average price is $41.43. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. Vera Therapeutics, Inc. has a twelve month low of $19.07 and a twelve month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the prior year, the company earned ($0.81) EPS. As a group, research analysts expect that Vera Therapeutics, Inc. will post -6.23 EPS for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.